Abstract: Long-term use of topical nasal steroids (especially older generation steroids) has been shown to elevate intraocular pressure (IOP), but newer intranasal steroids are thought to have a minimal effect on IOP because of their low bioavailability. This study aimed to investigate alterations in IOP with two commonly used intranasal steroids for a 6-month period of time. One-hundred allergic rhinitis patients, divided equally into two groups, used mometasone furoate and fluticasone furoate intranasal steroids for 6 months. IOPs were measured before treatment and repeated at the 3rd, 6th, 12th, and 24th weeks of treatment. The IOPs of the groups were then compared. No statistically significant alteration was observed between the groups during the treatment time period. It was found that new generation intranasal steroids can be used safely, and there may not be an increased risk of IOP elevation in prolonged use in normal healthy people.
Introduction
Topical nasal steroids are widely used by otolaryngologists to treat allergic rhinitis (AR) patients for a long period of time. 1 Prolonged use of these drugs can cause some adverse effects on eyes. The literature has reported posterior subcapsular cataract and elevated intraocular pressure (IOP) levels with long-term use of intranasal steroids. 2, 3 IOP has a circadian rhythm, and one study has described a relationship between plasma cortisol levels and IOP fluctuation. 4 IOP can vary with age, systemic/local factors, and medications. 5 Although systemic, topical or ophthalmic use of steroids can increase IOP, the effect of intranasal use of steroids on IOP is controversial. 3, 6 This study aimed to investigate IOP alterations in AR patients using two common intranasal steroids for a 6-month period of time.
Materials and methods
One-hundred patients (41 women, 59 men; mean age ± standard deviation: 47.88±18.90) were enrolled in this study. All patients were diagnosed with AR as defined by the Allergic Rhinitis and Its Impact on Asthma (ARIA) study, 7 and all of the patients were treated with intranasal steroid sprays. Half of the patients (50 subjects) used mometasone furoate nasal spray (Nasonex, MSD, Merck & Co., Inc., Whitehouse Station, NJ, USA; 200 µg/day) and the other half (50 subjects) used fluticasone furoate nasal spray (Avamys, GlaxoSmithKline, London, UK; 110 µg/day). Each patient underwent a thorough otolaryngological and ophthalmological examination before treatment. Fundoscopic examinations were performed on all 100 subjects, and IOPs were measured using Goldmann Applanation Tonometry. All eye measurements were carried out by the same ophthalmologist, all the measurements were performed at the same time between 1 pm and 2 pm, and IOP was measured at the 3rd, 6th, 12th, and 24th weeks of treatment for each patient. This study conforms to the tenets of the Declaration of Helsinki and it was approved by the Ethics Committee of Adıyaman University, and written informed patient consent was obtained. Exclusion criteria for study participation were additional nasal illnesses, such as polyposis or chronic sinusitis, ophthalmic or systemic disorders, previous steroid use (topical/systemic), known ocular hypertension or glaucoma patients, and under the age of 18.
Data analysis was performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA). Age distribution was not normal, and Mann-Whitney U-test was used for comparison of both groups. IOP measurements' data distribution was normal, Student's t-test was used for paired comparisons between preoperative measurement and other time intervals. A P-value ,0.05 was considered statistically significant.
Results
One-hundred patients (50 subjects in each group) were included in this prospective study. The mean age in the fluticasone furoate and the mometasone furoate groups was 47.48±19.16 and 48.28±18.83, respectively. No statistically significant differences in age averages and sex distribution were found between the groups (P.0.05) ( Table 1) .
Averages for the IOP for the right and left eyes for the initial, 3rd, 6th, 12th, and 24th weeks of treatment are shown in Tables 2 and 3 for both steroid groups. Although some IOP fluctuations were observed, no statistically significant differences were found on the paired comparisons of the initial and the four time measurements (P.0.05).
Discussion
Intranasal steroids are used to effectively treat perennial and seasonal AR, and they consist of two generations of steroids. First-generation intranasal steroids (budesonide, beclomethasone dipropionate, and triamcinolone acetonide) have more systemic bioavailability in comparison to second-generation intranasal steroids (mometasone furoate, fluticasone propionate, and fluticasone furoate). While systemic bioavailability can increase up to 49% with older generation steroids, it is ,1% for fluticasone and mometasone furoate. 8 Absorption from nasal and gastrointestinal mucosa are the ways that intranasal steroids can enter the blood stream. Direct pass occurs via nasal mucosa without first-pass metabolism, so this can excessively injure the end organs. On the other hand, steroids absorbed from the gastrointestinal system undergo degradation in the liver, so less active metabolites can reach the end organs. 9 It has been reported that the amount of steroids absorbed from the nasal passages is minimal in comparison to the amount of steroids absorbed from the gastrointestinal tract. 8 However, inflammation is present in baseline rhinitis and this may cause a high absorption of steroids from nasal mucosa. 10 IOP depends on humor aqueous secretion from the ciliary process and its excretion to episcleral veins via trabecular meshwork. However, both formation and excretion are balanced. 5 There are some theories as to how steroid-induced IOP elevation occurs. Altered electrolyte imbalance, an increment in trabecular meshwork mucopolysaccharides, steroid-induced vasoconstriction in episcleral veins, and actin remodeling in trabecular meshwork can all lead to elevated IOP. 9, 11 It is also important to note that trabecular cells contain steroid receptors and this can be associated with resistance to the outflow of humor aqueous. 9, [12] [13] [14] The literature has reported contradictory findings regarding inhaler/nasal steroid usage and IOP. The first report about IOP and inhaled steroids was published in 1993 by Dreyer. 15 Glaucoma was reported in three patients during treatment with inhaled beclomethasone dipropionate. Opatowsky et al 3 also showed IOP elevation in three cases with inhaled and/or nasal beclomethasone dipropionate treatment. They concluded that this effect was reversible with elimination of the drugs. Moreover, Öztürk et al 13 followed-up patients who underwent endoscopic sinus surgery and who used budesonide and beclomethasone dipropionate on average for 8.8 months, and no statistically significant increase in 16 performed a similar study in which patients used fluticasone propionate for 6 weeks postoperatively, and neither IOP elevation nor posterior subcapsular cataract formation was observed. In a doubleblind prospective experimental study, the effect of nasal steroids (fluticasone propionate, mometasone furoate, and beclomethasone dipropionate) on the IOPs of patients with rhinitis was studied for 1 year; significant alteration in the IOPs, which were found to be within normal limits, was not observed. 5 In our study, we encountered similar findings; no statistically significant elevation was observed in the IOP parameters during the 6-month period with fluticasone and mometasone nasal steroids.
Steroid-induced IOP elevation can occur in patients with risk factors, including primary open angle glaucoma, diabetes mellitus, high myopia, connective tissue disorders, and a first degree relative with primary open angle glaucoma. 9, 17 Although patients with ocular hypertension and glaucoma have a tendency for IOP increment when using nasal steroids, contradictory findings have also been reported in this patient group. Garbe et al 12 investigated the effect of normal and high dosage inhaler steroid treatment on IOP in glaucomatous and ocular hypertensive patients, and they suggested that only high dose administration of these steroids for 3 or more months was associated with ocular hypertension and glaucoma.
In a small placebo-controlled, prospective, randomized trial, 19 patients, with primary open angle glaucoma or ocular hypertension, used beclomethasone dipropionate nasal spray for 6 weeks, and the authors concluded that no statistically significant increment was observed in IOP when compared with the placebo group. 10 The only study that found detrimental effects of nasal steroids was by Bui et al, 14 and they stated that discontinuing nasal steroids revealed a statistically significant reduction in IOP in patients with glaucoma and ocular hypertension (12 patients, eleven with glaucoma and one with ocular hypertension). While they concluded that nasal steroids might elevate IOP, the patients in their study used different types of nasal steroids (both first-and second-generation steroids), and measurements were not selectively performed for each type of steroid.
As a result of our study, we did not observe IOP increment with prolonged use of mometasone furoate and fluticasone furoate nasal sprays during 6-month follow-up. We think that there may not be a risk for increased IOP in healthy subjects.
Conclusion
New generation intranasal steroids can be used safely with ,1% systemic bioavailability in normal healthy people. Although close follow-up is recommended for at-risk patients, this treatment recommendation may change if wider patient group studies examine the use of new generation nasal steroids in the future. 
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